Patent expirations won't hold back success of some drug firms

11/18/2003 | Bloomberg Businessweek

Although many drug firms are facing patent expirations next year, investors are bullish on several companies. For example, Pfizer is favored among investors based on anticipated 2004 sales of its recently approved drug for congestive heart failure. Abbott recently launched Humira, a rheumatoid arthritis drug that could be a hit, while Wyeth's lack of patent expirations could outweigh its weak pipeline.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX